Bariatric procedure volumes during changes to coordinated care and incretin therapy expansion in Poland: a retrospective study of 30 centers, 2022–2025

Abstract Introduction: Expanding incretin pharmacotherapy has prompted debate about declining bariatric surgery use. We examined procedure volumes during changes to Poland's coordinated bariatric care pilot (KOS-BAR) and growth in incretin drug sales. Methods: We analyzed National Health Fund procedure counts for 2022–2025 in 30 centers selected in a health technology assessment report. Nineteen centers had participated in the pilot and 11 had not. The principal comparison was total panel volume in 2023 versus 2024. Four exploratory exact rank-sum and sign tests assessed center changes, with Holm adjustment. Regulations and separate drug-sales aggregates provided context. Results: Panel volume increased from 5 515 procedures in 2022 to 7 667 in 2023, decreased to 6 735 in 2024 (− 12.2%), and increased to 7 455 in 2025 (+ 10.7%). The 2024 decline comprised 1 023 fewer procedures in pilot centers and 91 additional procedures elsewhere. Median center-level changes were − 25.3% and + 1.2%, respectively (Holm-adjusted p = 0.0112). Regulations implied a 177-day interval outside the pilot's operative timetable in 2024, without establishing center-specific suspension. Combined nominal sales value of semaglutide and tirzepatide increased from PLN 1.376 billion in 2024 to approximately PLN 3.056 billion in 2025. Procedure volume remained 2.8% below its 2023 peak. Conclusion: Expanding incretin sales were not accompanied by a sustained decline in panel volume. The decline in pilot centers was followed by recovery, highlighting care organization as context. Selected centers, annual aggregation, and sales measures preclude national extrapolation or identification of policy and drug effects.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-13
DOI
https://doi.org/10.21203/rs.3.rs-11347038/v1
Primary Topic
Bariatric Surgery and Outcomes
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Bariatric procedure volumes during changes to coordinated care and incretin therapy expansion in Poland: a retrospective study of 30 centers, 2022–2025

Michal Robert Janik, Ali Aminian, Piotr Major
3 links
Research Square
Bariatric Surgery and Outcomes
preprint

Bariatric procedure volumes during changes to coordinated care and incretin therapy expansion in Poland: a retrospective study of 30 centers, 2022–2025

Michal Robert Janik, Ali Aminian, Piotr Major
preprint en

Abstract

Abstract Introduction: Expanding incretin pharmacotherapy has prompted debate about declining bariatric surgery use. We examined procedure volumes during changes to Poland's coordinated bariatric care pilot (KOS-BAR) and growth in incretin drug sales. Methods: We analyzed National Health Fund procedure counts for 2022–2025 in 30 centers selected in a health technology assessment report. Nineteen centers had participated in the pilot and 11 had not. The principal comparison was total panel volume in 2023 versus 2024. Four exploratory exact rank-sum and sign tests assessed center changes, with Holm adjustment. Regulations and separate drug-sales aggregates provided context. Results: Panel volume increased from 5 515 procedures in 2022 to 7 667 in 2023, decreased to 6 735 in 2024 (− 12.2%), and increased to 7 455 in 2025 (+ 10.7%). The 2024 decline comprised 1 023 fewer procedures in pilot centers and 91 additional procedures elsewhere. Median center-level changes were − 25.3% and + 1.2%, respectively (Holm-adjusted p = 0.0112). Regulations implied a 177-day interval outside the pilot's operative timetable in 2024, without establishing center-specific suspension. Combined nominal sales value of semaglutide and tirzepatide increased from PLN 1.376 billion in 2024 to approximately PLN 3.056 billion in 2025. Procedure volume remained 2.8% below its 2023 peak. Conclusion: Expanding incretin sales were not accompanied by a sustained decline in panel volume. The decline in pilot centers was followed by recovery, highlighting care organization as context. Selected centers, annual aggregation, and sales measures preclude national extrapolation or identification of policy and drug effects.

Research Square
Jagiellonian University (PL), Cleveland Clinic (US), Wojskowy Instytut Medycyny Lotniczej (PL)
Good health and well-being
Bariatric Surgery and Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon